39 results about "Glycosphingolipid" patented technology

The present invention relates to a method for the production of a sialylated glycosphingolipid, the method comprising the steps of: ─ providing a glycosphingolipid, a sialic acid donor, and an enzyme having a trans-sialidase activity, ─ mixing said glycosphingolipid with said sialic acid donor in the presence of said enzyme having trans-sialidase activity, thereby producing said sialylated glycosphingolipid, and wherein the sialic acid donor is 3´-sialyllactose.

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

The invention provides a method for detecting amino acid in a compound encephalokinin injection by using an LC-MS (Liquid Chromatography-Mass Spectrometry) method, which has the characteristics of simplicity and convenience in operation, and good precision, stability and recovery rate. The method can be used for detecting the content of 13 amino acids in the compound brain peptide injection, including histidine, phenylalanine, lysine, tyrosine, asparagine, methionine, valine, leucine, serine, arginine, proline, alanine and isoleucine. The detection method is high in detection sensitivity and can be applied to internal quality component research, intermediate component control and quality identification of the product. The detection method can also be used for evaluating the inherent quality of the compound encephalokinin injection, further ensuring the stability of the inherent quality of the product and providing technical reference.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and / or higher levels of glycosphingolipids.

Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by progressive myocardial fibrofatty infiltration. Compositions in the treatment of fibrofatty accumulation and its pathogenesis in ACM include activators of glycosphingolipid (GSL) glycosyltransferase, β-1,4-galactosyltransferase- V (β-1,4-GalT-V).

The invention provides a plant glycosphingolipid extraction method, which comprises: taking a plant material, grinding liquid nitrogen, adding a hot ethanol solution (containing beta-mercaptoethanol), carrying out oscillation extraction at a high temperature, carrying out high-temperature high-speed centrifugation, taking the supernatant, carrying out low-temperature precipitation, and carrying out high-speed centrifugation to obtain a crude extract; washing the crude extract with acetone and diethyl ether, removing the organic solvent through high-speed centrifugation, adding a dissolving solution (tetrahydrofuran, methanol and water), carrying out vortex uniform mixing, carrying out high-temperature dissolution, filtering, and carrying out vacuum centrifugal drying on the filtrate to obtain a crude product; adding n-butyl alcohol and water into the crude product, dissolving, precipitating and centrifuging at high temperature, taking an upper layer n-butyl alcohol phase, and performing vacuum centrifugal drying to obtain a target product. The extraction method provided by the invention has the advantages of high extraction efficiency and time saving, and more importantly, small-weight plant material extraction can be effectively realized by virtue of simple equipment, and the sample size required by mass spectrum identification of GIPCs composition and ion chromatography identification of GIPCs glycosyl composition can be obtained.

The invention relates to a glycosphingolipid derivative as well as a preparation method and application thereof. Pulullan is activated, DMEDA is adopted to selectively remove part of acetyl, trichloroacetonitrile (Cl3CCN) is introduced to generate an active intermediate, meanwhile, hydroxyl of phytosphingosine is protected to form a stable ketal structure, and side reaction is avoided. Activated pullulan and hydroxyl-protected phytosphingosine are subjected to a condensation reaction under the action of an acid catalyst, and then high-purity glycosphingolipid derivatives are prepared through deprotection treatment and purification. The compound has excellent amphipathy, shows good moisturizing performance and light aging resistance, and can be widely applied to the fields of cosmetics, medicines and functional materials. The method has the advantages of mild reaction conditions and high efficiency, and avoids the problems of poor reaction selectivity and many impurities in the traditional technology.

A composition for young children comprising glycosphingolipids. The present invention relates to a composition comprising one or more glycosphingolipids, to a nutritional formula for children comprising said composition, to the use of said composition for supporting healthy growth and development of young children, in particular infants, and for dietary management of symptoms related to inflammation of the gastrointestinal tract system of said young children. In particular, the present invention relates to a composition comprising one or more compounds of formula (1) or salts thereof: wherein R1 is a C13-C17 alkyl chain; r2 is a C15-C19 alkyl chain; and R3 is a glycosyl moiety selected from Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-or Neu5Ac [alpha] 2-8-Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-. Children's nutritional formulas comprising the composition are also provided.

The present invention describes a novel method for the isolation of a glycosphingolipid lacking the amide-linked fatty acyl group, the method comprising the steps of: providing a solution comprising said glycosphingolipid of formula (1) or a salt thereof, and one or more contaminants, diafiltration of said solution, thereby obtaining a diafiltration retentate (DFR) comprising said glycosphingolipid, or salt thereof, by using a membrane having a MWCO of 100-300 kDa, thereby isolating said glycosphingolipid or salt thereof from the one or more contaminants.

A composition comprising one or more compounds of formula (1), or salts thereof: (1) wherein R1 is a C13-C17 alkyl chain; R2 is a C15-C19 alkyl chain, preferably C18; and R3 is a glycosyl moiety selected from Neu5Acα2-3-Galβ1-4-Glcβ1-, or Neu5Acα2-8-Neu5Acα2-3- Galβ1-4-Glc β1-. Child nutritional formulas containing the composition are also provided.

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

The present invention relates to a method for producing a sialylated glycosphingolipid, comprising the steps of:-providing a glycosphingolipid, a sialic acid donor and an enzyme having transsialidase activity,-mixing the glycosphingolipid with the sialic acid donor in the presence of the enzyme having transsialidase activity, the sialylated glycosphingolipid is a sialylated glycosphingolipid, and wherein the sialic acid donor is 3 '-sialylated lactose.

The invention discloses soothing face cream with a moisturizing function and a preparation method of the soothing face cream, and belongs to the technical field of cosmetic face cream. Comprising the following components in percentage by mass: 3%-5% of a hydrogenated styrene-butadiene block copolymer, 2%-4% of isopropyl myristate, 1%-3% of glycosphingolipids, 2%-4% of dipolypentaerythritol hexanoate, 1%-3% of c12 / 13 alcohol lactate, 0.5%-1.5% of tocopheryl acetate, 0.1%-0.5% of bisabolol, 2%-5% of a fermentation extract and the balance of water. 1%-3% of a kosteletzkya virginica extract, 0.5%-1.5% of an embelia fortuneana extract, 0.5%-1.5% of an apium graveolens seed extract, 0.5%-1.5% of an astragalus membranaceus extract, 0.5%-1.5% of a phellodendron amurense bark extract, 2-5% of a vegetable oil composite liquid crystal emulsifier, 8%-15% of a humectant, 0.3%-0.8% of a preservative, 0.05%-0.15% of disodium EDTA and the balance of water. According to the invention, rape oil amide propyl-dimethylamine is prepared into a vegetable oil composite liquid crystal emulsifier to be applied to a face cream formula, an oil-in-water emulsion system with efficient moisturizing and relieving effects and strong stability is constructed, good smearing property and rapid absorbability of the face cream are realized, and the durability of the moisturizing and relieving effects of the face cream is remarkably improved.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions, including complex sphingolipids, such as monosialic acid ganglioside 1 (GM1), monosialic acid ganglioside 2 (GM2), and monosialic acid ganglioside 3 (GM3). In some embodiments, the present disclosure provides biological production of glycosphingolipids. In still further embodiments, the present disclosure provides for the biological production of gangliosides.

The application relates to a sample processing method and a mass spectrometry detection method for selective photocatalytic desugar of glycosphingolipids. The sample processing method specifically comprises the following steps: (1) dissolving a sample in an alkaline protic solvent; (2) dispersing titanium dioxide particles in the sample; and (3) performing a photocatalytic reaction under ultraviolet light irradiation, centrifuging, and obtaining a photocatalytically processed sample solution. The mass spectrometry detection method specifically comprises the following steps: feeding the photocatalytically processed sample solution into a mass spectrometer to perform primary mass spectrometry detection, comparing the photocatalytically processed sample solution with a sample extraction solution without photocatalytic processing, screening a primary mass spectrometry peak that may be a glycolipid decomposition product through comparative analysis, and performing further secondary mass spectrometry detection to analyze the accurate molecular structure of the glycolipid. The method can selectively and rapidly and efficiently remove the sugar group head of glycolipids in the presence of complex lipid groups, and can be used for subsequent mass spectrometry detection and analysis. Through comparison of mass spectrometry peaks before and after removal, glycolipid peaks in complex mass spectrometry peaks can be effectively and rapidly and accurately found, important chemical information for rapid locking of correct candidate substances in the primary mass spectrometry qualitative process is provided, and glycolipid decomposition products can also obtain more abundant carbon chain structure information than original glycolipids to assist in qualitative analysis.

Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.

The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

The present invention describes a novel method for the isolation of a glycosphingolipid lacking the amide-linked fatty acyl group, the method comprising the steps of: providing a solution comprising said glycosphingolipid of formula (1) or a salt thereof, and one or more contaminants, diafiltration of said solution, thereby obtaining a diafiltration retentate (DFR) comprising said glycosphingolipid, or salt thereof, by using a membrane having a MWCO of 100-300 kDa, thereby isolating said glycosphingolipid or salt thereof from the one or more contaminants.

The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

FIELD: cosmetics.SUBSTANCE: cosmetic composition in the form of a cream-gel for skin cleansing contains purified water; an emulsifier consisting of cetyl alcohol, glyceryl stearate, PEG-75 stearate, ceteth-20 and steareth-20; glycerin; coco-glucoside; a co-surfactant consisting of purified water, glyceryl oleate and coco-glucoside; cetearyl alcohol; caprylic / capric triglyceride; panthenol; butylene glycol; squalane; oat extract; sodium acrylate / sodium acryloyldimethyl taurate copolymer; cocamidopropyl betaine; cholesterol; ceramide complex including: ceramides NP, AP, AS, NG, glycosphingolipids, hydrogenated lecithin and auxiliary components; fructooligosaccharides; hydroxyacetophenone; preservative consisting of 1,2-hexanediol and caprylyl glycol; tocopheryl acetate; fragrance; arginine and disodium EDTA, in a certain ratio of components, wt.%.EFFECT: relisble removal of impurities from the skin's surface, restoration of the damaged protective barrier of the skin during washing without causing excessive dryness of the skin, relief of irritation and moisturization of the skin.1 cl, 3 tbl, 4 ex

The invention discloses a method for extracting ceramide and glycosphingolipid from the byproduct of liquor, the waste lees, and belongs to the technical field of compound extraction. The invention provides a method for extracting ceramide and glycosphingolipid, which uses the byproduct of liquor, the waste lees, as raw materials, and sequentially undergoes the steps of drying, extraction, alkali adjustment, filtration, acid adjustment, concentration, extraction, recrystallization, etc., to finally obtain free ceramide and glycosphingolipid. The invention extracts ceramide and glycosphingolipid with high economic value from the byproduct of liquor, turns waste into treasure, recycles resources, improves resource utilization, and has significant economic and environmental benefits.

The invention relates to a soft hydrogel contact lens, especially a silicone hydrogel contact lens, which has a capability of delivering a hydrophobic comfort agent into the eye of a wearer. The hydrophobic comfort agent includes without limitation a monoglyceride, a diglyceride, a triglyceride, a glycolipid, a glyceroglycolipid, a sphingolipid, a sphingo-glycolipid, a phospholipid, a fatty acid, a fatty alcohol, a hydrocarbon having a C12-C28 chain in length, a mineral oil, a silicone oil, or a mixture thereof. It can be released from the soft hydrogel contact lens into the eye of a wearer when being worn so as to strengthen and stabilize the tear film lipid layer and alleviate the dryness of the eye.

The present invention describes a novel process for the isolation of glycosphingolipids lacking amide-linked fatty acyl groups, comprising the steps of providing a solution comprising the glycosphingolipids of formula (1) or salts thereof and one or more contaminants, percolating the solution by using a membrane having an MWCO of 100-300 kDa, separating the percolated glycosphingolipids from the percolated glycosphingolipids, and separating the percolated glycosphingolipids from the percolated glycosphingolipids. And separating the glycosphingolipids or salts thereof from one or more contaminants, thereby obtaining a diafiltration trapped fluid (DFR) comprising the glycosphingolipids or salts thereof, thereby separating the glycosphingolipids or salts thereof from the one or more contaminants.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

The present invention describes a novel method for isolating sphingoglycolipids lacking amide-linked fatty acid acyl groups. The method comprises the steps of: preparing a solution containing the sphingoglycolipid of formula (1) or a salt thereof and one or more impurities; and diafiltration the solution using a membrane having a MWCO of 100 kDa to 300 kDa to obtain a diafiltration retaining liquid (DFR) containing the sphingoglycolipid or salt thereof, thereby isolating the sphingoglycolipid or salt thereof from one or more impurities.

The present invention relates to the fusion proteins against a glycocalyx, found to be associated with several human post-translational modified proteins linked to cancer cell lines. The fusion proteins of the present invention are able to bind only to sialylated glycosphingolipids and sialylated glycoproteins and well as their independent constituents the monosaccharide sugars such as neu5ac, galnac and gal that constitute the glycocalyx. The products claimed can be used for diagnosis and treatment of various cancers. Apoptosis via Caspase 3 occurs in cancer cells when the fusion protein bound to targets is sequestered in lysosomes. The fusion protein is not seen in any other organelle of the cell except for lysosomes.

Provided are methods of synthesizing glycolipids. The methods combine chemical and enzymatic transformations to rapidly provide diverse natural and functionalized glycolipids in a high convergent matter. Stepwise enzymatic elongation of a carbohydrate chain of a common glycolipid precursor, compound (1), provides glycan intermediates of Formula (II), using sugar-nucleotides as glycosyl donors and glycosyltransferases as enzymes. Also provided are glycan intermediates of Formula (II) and alkene intermediates of Formula (IV) and methods of preparing same.

The present invention relates to a composition for improving cognitive function, the composition improving cognitive function by comprising: a mixture of phospholipids comprising phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, glycosphingolipids, and gangliosides; one or more types of neutral lipids selected from the group consisting of EPA and DHA; sphingolipids; and oil.